Lord, Abbett & Co’s Relay Therapeutics RLAY Stock Holding History
Bought
Maintained
Sold
Other funds holding RLAY
Lord, Abbett & Co's RLAY Position: Q3 2026 in Review
Lord, Abbett & Co increased its Relay Therapeutics (RLAY) stake by 15% in Q3 2026, buying an estimated $1.2M and bringing the position to 473,358 shares worth $8.54M. The position accounts for 0.03% of the portfolio, ranked #415.
Lord, Abbett & Co first reported a position in RLAY in Q3 2020 and has held it in 3 quarters since. The position peaked at $9.7M in Q3 2020. 261 funds tracked by Wall St. Rank hold RLAY as of Q3 2026.
- Lord, Abbett & Co held 473,358 shares of Relay Therapeutics worth $8.54M as of Q3 2026.
- Lord, Abbett & Co bought 62,635 Relay Therapeutics shares in Q3 2026, an estimated $1.2M.
- Relay Therapeutics made up 0.03% of Lord, Abbett & Co's portfolio in Q3 2026, its #415 holding.
- Lord, Abbett & Co first reported a position in Relay Therapeutics in Q3 2020 and has held it in 3 quarters since.
- Lord, Abbett & Co's Relay Therapeutics position peaked at $9.7M in Q3 2020.
- 261 funds tracked by Wall St. Rank held Relay Therapeutics as of Q3 2026.
Based on Lord, Abbett & Co's 13F filing for Q3 2026, filed 13 Nov 2026.